BillionToOne Job Trends
9
Active Jobs (Last 14 Days)
3
Fresh Jobs (Last 3 Days)
89%
Jobs with Salary Data
Recent Job Posting Activity (30 Days)
Job Category Distribution
Current BillionToOne Jobs, Salary Data, and Stats
In the last two weeks, BillionToOne has posted 9 positions. None of those roles offer remote or hybrid work. We've been tracking BillionToOne since March 17, 2025.
Career Tracks Currently Hiring
Currently Hiring Office Locations
Central Missouri Wisconsin Houston, TX Charlotte East, NC Grand Rapids North, MI and 31 moreCurrent BillionToOne Jobs
Last updated: Apr 3, 2025
Showing 9 active jobs. Active jobs were posted in the last 14 days. Fresh jobs were posted within the last 3 days. Click a row for more details.
Showing filtered results for ""
| Role | |
|---|---|
Account ExecutiveApply →Fresh
Apr 1 $117,000 - $142,000
Phoenix, AZBillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Regional Manager - Prenatal, South-Atlantic (Virginia/Delaware/New Jersey/Washington, D.C.)Fresh
Mar 31 Salary N/A Virginia/Delaware/New Jersey/Washington, D.C. Apply →Regional Manager - Prenatal, South-Atlantic (Virginia/Delaware/New Jersey/Washington, D.C.)Apply →Fresh
Mar 31 Salary N/A
Virginia/Delaware/New Jersey/Washington, D.C.BillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Senior FP&A ManagerApply →Fresh
Mar 31 $173,400 - $193,800
Menlo Park, CABillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Director, Data ScienceApply →Data
Mar 27 $0 - $125
Menlo Park, CABillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Account ExecutiveApply →Mar 26 $117,000 - $142,000
Central IllinoisBillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Oncology Account ExecutiveApply →Med Practice
Mar 26 $231,650 - $300,700; $147,900 - $163,200
IndianaBillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
LIMS InternApply →Mar 25 $0 - $125
Menlo Park or Union City, CABillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Account ExecutiveApply →Mar 21 $117,000 - $142,000
Northeast TexasBillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |
Automation Service Engineer IIApply →Tech
Mar 21 $61 - $66
Union City, CABillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™ , the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy... | |